A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs DW 1029M (Primary) ; Linagliptin
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Acronyms PLID
- Sponsors Dong Wha Pharmaceutical
- 01 Aug 2017 Results published in the Clinical Pharmacology in Drug Development
- 26 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Feb 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.